Results 51 to 60 of about 681,398 (156)

Withdrawal pain following patients discontinuing Trk inhibitors. [PDF]

OBJECTIVE: This article aims to expand on the existing literature regarding the incidence of withdrawal pain following discontinuation of Trk inhibitors and to explore strategies that mitigate this withdrawal pain.
Lindsay, Sheila, Chin, Alan, Bergsland, Emily, Kang, Hyunseok   +3 more
core   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

Medicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti, Camilla Tavani, Elena Somenza, Nicolas Tassone, Antonio d'Amati, Marta Turati, Roberto Ronca   +6 more
wiley   +1 more source

Entrectinib: A potent new TRK, ROS1, and ALK inhibitor

, 2015
Introduction: Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation.
Giallombardo, Marco, Ignacio Gil-Bazo, Peeters, Marc, Antonio Russo, Christian Rolfo, Elisa Giovannetti, Francesco Passiglia, Peeters, M., Rolfo, C., Giovannetti, Elisa, Passiglia, Francesco, Raez, L., Marc Peeters, Russo, A., Giovannetti, E., Rossana Ruiz, Rolfo, Christian, Passiglia, F., Gil-Bazo, I., Raez, Luis, Gil-Bazo, Ignacio, Giallombardo, M., Marco Giallombardo, Ruiz, R., Russo, Antonio, Ruiz, Rossana, Luis Raez   +26 more
core   +1 more source

Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights

Molecules
Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively.
Amol T. Mahajan, Shivani, Ashok Kumar Datusalia, Carmine Coluccini, Paolo Coghi, Sandeep Chaudhary   +5 more
doaj   +1 more source

Laponite Network Controls FGF‐2 Release and Drives Functional Nerve Regeneration via 3D‐Printed Nerve Wrap Interfaces

Small Methods, EarlyView.
We developed a 3D‐printed nerve interface integrating a biomimetic nanocomposite hydrogel with sustained delivery of thermostable FGF‐2. The bioactive interface supports Schwann cell activity and myelination while providing a regenerative microenvironment.
Diego N. Rodriguez‐Sanchez, Akshat Joshi, Saeed Safari, Leticia A. M. de Carvalho, Kevin S. Muller, Uijin Kim, Luciana P. Cartarozzi, Meenakshi Kamaraj, Menekse Ermis, Natan R. de Barros, Alexandre L. R. de Oliveira   +10 more
wiley   +1 more source

CTNI-74. ON-TRK: A NON-INTERVENTIONAL STUDY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION SOLID TUMORS

, 2023
Increasingly, health authorities and the medical community are investing resources into evaluating real-world data (RWD) on precision biomarker-based treatments.
Burcoveanu, Domnita-Ileana, Passiglia, Francesco, Novello, Silvia, Trent, Jonathan, Laetsch, Theodore, Tabatabai, Ghazaleh, Norenberg, Ricarda   +6 more
core   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Neurotrophin receptors (Trk A, Trk B, and Trk C) in the developing and adult human retina

, 1999
In this study, the ontogeny and distribution patterns of three neurotrophin receptors (Trk A, Trk B, and Trk C) were examined in the human retinas. Immunohistochemistry was performed on sections of retina and optic nerve from fetuses (11-24 weeks of ...
Tapas C Nag, Shashi Wadhwa, Nag, Tapas C., Wadhwa, Shashi   +3 more
core   +1 more source

Preclinical Evaluation of the Oral Toxicity, Genotoxicity, and Safety Pharmacology of LPM4870108, a Novel Potent Tropomyosin Receptor Kinase Inhibitor

Pharmacology Research & Perspectives
Tropomyosin receptor kinase (Trk) inhibitors are an essential class of anticancer drugs treating NTRK gene fusions‐positive cancer. However, the potential for the emergence of on‐target resistance suggests newer Trk inhibitors with low drug resistance ...
Xiaochen Zhang, Baiyang Yuan, Chunmei Li, Hongbo Wang, Shujuan Wei, Jingwei Tian, Sijin Duan   +6 more
doaj   +1 more source